Lenalidomide

Sold as Revlimid. Every FDA application for this active ingredient: 1 branded and 20 generic.

As of Nov 13, 2026, FDA lists 21 applications for Lenalidomide (sold as Revlimid), first approved Dec 27, 2005, with 8 new uses approved and 0 published complete response letters.

• First approved: Dec 27, 2005
• Applications: 21
• New uses approved: 8
• Complete response letters: 0
• Medicare spending, 2024: $6.82B